BGB-11417-303

A Phase-III Randomized, Open-Label, Multicenter Study of Sonrotoclax-CD-20 Antibody Therapies Versus Venetoclax-Rituximab in Patients with Relapsed/Refractory CLL/SLL (CELESTIAL-RRCLL/CLL-RR1).
Description: The goal of this study is to compare how well sonrotoclax plus obinutuzumab works versus venetoclax plus rituximab in treating adults with relapsed and/or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). The study will also compare how well sonrotoclax plus rituximab works versus venetoclax plus rituxumab in treating adults with R/R CLL/SLL. The safety of these treatments will also be assessed.
Study Phase: Phase 3
Principal Investigator: Dr Carmel Waldron
Further information

CLL-18

A Phase 3 Multicentre, Randomised, Prospective, Open-Label Trial Of MRD-Guided Venetoclax/Pirtobrutinib VS. Fixed-Duration, Venetoclax/Pirtobrutinib VS. Fixed Duration, Venetoclax/Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Description: The primary objective of the study is to compare the efficacy of MRD-guided Venetoclax/Pirtobrutinib vs fixed-duration (15 cycles) Venetoclax/Pirtobrutinib and MRD-guided Venetoclax/Pirtobrutinib vs. fixed-duration (12 cycles) Venetoclax/Obinutuzumab by measuring progression-free survival (PFS) in patients with previously untreated chronic lymphocytic leukaemia (CLL)/small lymphocytic lymphoma (SLL)
Study Phase: Phase 3
Principal Investigator: Dr. Carmel Waldron
Further information

Enquire about a Cancer Clinical Trial

If you would like more information on Cancer Clinical Trials you can contact us.

Make an enquiry